Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Dermatologic side effects of thalidomide in patients with multiple myeloma.

Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV.

J Am Acad Dermatol. 2003 Apr;48(4):548-52.

PMID:
12664018
2.

Thalidomide in multiple myeloma: current status and future prospects.

Cavenagh JD, Oakervee H; UK Myeloma Forum and the BCSH Haematology/Oncology Task Forces..

Br J Haematol. 2003 Jan;120(1):18-26. No abstract available.

PMID:
12492572
3.

Thalidomide in chronic graft-versus-host disease after stem cell transplantation: effects on quality of life.

Miller S, Sharda S, Rodrigue J, Mehta P.

Int J Hematol. 2002 Nov;76(4):365-9.

PMID:
12463602
4.

Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.

Rajkumar SV, Hayman S, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR, Geyer S, Iturria N, Fonseca R, Lust JA, Kyle RA, Witzig TE.

J Clin Oncol. 2002 Nov 1;20(21):4319-23.

PMID:
12409330
5.

Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions.

Jones SG, Dolan G, Lengyel K, Myers B.

Br J Haematol. 2002 Nov;119(2):576-7. No abstract available.

PMID:
12406106
6.

The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma.

Grover JK, Uppal G, Raina V.

Ann Oncol. 2002 Oct;13(10):1636-40.

PMID:
12377654
7.

[Lung toxicity due to thalidomide].

Carrión Valero F, Bertomeu González V.

Arch Bronconeumol. 2002 Oct;38(10):492-4. Spanish.

8.

Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome.

Kakimoto T, Hattori Y, Okamoto S, Sato N, Kamata T, Yamaguchi M, Morita K, Yamada T, Takayama N, Uchida H, Shimada N, Tanigawara Y, Ikeda Y.

Jpn J Cancer Res. 2002 Sep;93(9):1029-36.

PMID:
12359057
9.

Thalidomide for the treatment of relapsed and refractory multiple myeloma.

Cool RM, Herrington JD.

Pharmacotherapy. 2002 Aug;22(8):1019-28. Review.

PMID:
12173786
10.

Thromboembolism in patients on thalidomide for myeloma.

Bowcock SJ, Rassam SM, Ward SM, Turner JT, Laffan M.

Hematology. 2002 Feb;7(1):51-3.

PMID:
12171777
11.

Thalidomide as an anti-cancer agent.

Kumar S, Witzig TE, Rajkumar SV.

J Cell Mol Med. 2002 Apr-Jun;6(2):160-74. Review.

12.

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.

Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L, Tricot G.

Blood. 2002 Aug 15;100(4):1168-71.

13.

Thalidomide in the treatment of multiple myeloma.

Rajkumar SV.

Expert Rev Anticancer Ther. 2001 Jun;1(1):20-8. Review.

PMID:
12113124
14.

Thalidomide-associated gynecomasty in a patient with multiple myeloma.

Pulik M, Genet P, Lionnet F, Touahri T.

Am J Hematol. 2002 Jul;70(3):265. No abstract available.

15.
16.

Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.

Zangari M, Saghafifar F, Anaissie E, Badros A, Desikan R, Fassas A, Mehta P, Morris C, Toor A, Whitfield D, Siegel E, Barlogie B, Fink L, Tricot G.

Blood Coagul Fibrinolysis. 2002 Apr;13(3):187-92.

PMID:
11943931
17.

Current therapy of multiple myeloma.

Kyle RA.

Intern Med. 2002 Mar;41(3):175-80. Review.

18.

Hypothyroidism in patients with multiple myeloma following treatment with thalidomide.

Badros AZ, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B, Tricot G.

Am J Med. 2002 Apr 1;112(5):412-3. No abstract available.

PMID:
11904117
19.

Thalidomide: 40 years on.

Diggle GE.

Int J Clin Pract. 2001 Nov;55(9):627-31. Review.

PMID:
11770361
20.

Therapeutic dilemmas with thalidomide in multiple myeloma: case discussions.

Desikan RK, Jagannath S.

Semin Oncol. 2001 Dec;28(6):593-6.

PMID:
11740815

Supplemental Content

Support Center